MedTrace Logo

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

NCT05928585 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-02-07

No results posted yet for this study

Summary

The goal of this clinical trial is to test safety of the investigational product in healthy volunteers. The main questions it aims to answer is when HIB210 is administered as multiple doses, is it:

1. Safe
2. Well tolerated
3. Does the body absorb and eliminate HIB210 as expected

Conditions

  • Immune System Diseases
  • Autoimmunity

Interventions

DRUG

HIB210

Experimental monoclonal antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • HI-Bio, A Biogen Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · HI-Bio, A Biogen Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2024-06-10
Completion
2024-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05928585 on ClinicalTrials.gov